650 private hospitals in Haryana to withdraw from Ayushman Bharat scheme over unpaid dues
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
In a massive blow to beneficiaries of the Ayushman Bharat health scheme, around 650 private hospitals across Haryana are set to stop providing treatment under the programme from August 7, unless the government clears outstanding reimbursements amounting to ₹500 crore, the Indian Medical Association 's Haryana unit warned on Tuesday.Calling the situation a 'chronic breakdown' of the scheme's administration in the state, the IMA said hospitals have received only 10–15% of their billed amounts since March. The mounting dues have left many facilities cash-strapped, with some already turning away patients or dipping into internal reserves to stay afloat.'The situation is worse than before. Hospitals cannot continue offering free treatment under the scheme without timely reimbursements. We're now at a point where running the system is financially impossible,' said Dr Mahavir Jain, president of IMA (Haryana).Despite repeated appeals, the Joint CEO for Ayushman Bharat in Haryana, Ankita Adhikari, did not respond to requests for comment till Tuesday evening.Hospitals in Gurgaon — including Park Hospital, Centre for Sight, Pushpanjali Hospital, Muskaan Dentals, and Kamla Hospital — are among those planning to suspend services. A doctor at one of the facilities confirmed: 'We will stop new admissions under Ayushman Bharat from Aug 7. Emergency services will continue, but planned procedures will be on hold.'The Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), launched by the Centre in 2018, aims to provide cashless health coverage of up to ₹5 lakh annually to economically vulnerable families. However, delays in processing claims and disbursing payments have increasingly strained its implementation.The IMA had issued a similar warning earlier in January, but withdrew after government assurances. This time, doctors say they've reached a breaking point.Patients relying on the scheme fear the impact will be devastating.'This scheme saved my life during the Covid-19 pandemic, but now I am not sure if I'll get treatment when I need it,' said Kamlesh Singh, a 41-year-old driver in Gurgaon who is awaiting surgery for an ear infection.Unless the state administration intervenes swiftly, the withdrawal of private hospitals could severely limit access to critical healthcare for thousands of low-income patients across Haryana.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
3 hours ago
- Hans India
Delhi CM Gupta inaugurates multispeciality hospital in Kailash Colony
Delhi Chief Minister Rekha Gupta on Sunday inaugurated the SSB Multispeciality Hospital in Kailash Colony, which promises to offer round-the-clock medical services at reasonable rates, officials said. The hospital features advanced services such as robotic knee replacement facility and has dedicated departments for gastroenterology, respiratory care, nephrology, and neuro and spine surgery, they said. Hospital chairperson Shyam Sundar Bansal said it will soon apply for empanelment under the Ayushman Bharat health insurance scheme of the Centre. Speaking at the event, Gupta said according to a World Health Organization (WHO) report, India has less than one hospital bed available per 1,000 people, stressing that such challenges can be addressed if the government and the private sector work in tandem in a focused manner. Delhi government aims to develop the national capital into a global medical hub, drawing patients from across the country and abroad, she said. The chief minister mentioned the recent installation of an advanced machine at the GB Pant Hospital that can generate a complete DNA profile from just a single drop of blood as a step in this direction. She also claimed that many hospitals constructed during the tenure of the previous (AAP) government were left incomplete or lacked sufficient resources. "We are now bringing all such hospitals under the public-private partnership (PPP) model to ensure their full-scale functioning," Gupta said. BJP MP Bansuri Swaraj and local MLA Shikha Rai were present at the inauguration ceremony.
Time of India
4 hours ago
- Time of India
Kerala: Kannur's beloved 'two-rupee doctor' Rairu Gopal passes away at 80
Kerala 's popular doctor, Rairu Gopal , known to provide health care services at a modest fee to people, died on Sunday. He was 80. The doctor earned the sobriquet ' Two Rupee Doctor ' as he often took just that much as his consulting fee from patients. The doctor, who left his mark on the field of healthcare services , was honoured with the IMA award for the best family doctor in the state. During his career, the doctor provided his noble service to more than 18 lakh patients. Explore courses from Top Institutes in Please select course: Select a Course Category Technology Management MBA Cybersecurity Public Policy Finance Artificial Intelligence healthcare PGDM Data Analytics Product Management MCA Leadership Others Operations Management Data Science Healthcare others Project Management Data Science Degree Digital Marketing CXO Design Thinking Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details Earlier today, Chief Minister Pinarayi Vijayan described doctor Rairu Gopal "as the people's doctor," noting that his readiness to serve for such a nominal fee was a source of immense relief for poor patients. "For half a century, he charged only two rupees for consultations, making healthcare accessible to all. His willingness to serve was a great comfort to countless patients," the Chief Minister said, according to the Public Relations Officer (PRO). Doctor Gopal was known to start consultations from 3 am in a manner that was convenient for students and workers alike. Seeing hundreds of patients daily. For many patients he was more than a doctor as he often provided them with the care of a father or brother. Live Events
Economic Times
6 hours ago
- Economic Times
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions. Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
